LUCIUS 卢修斯 奎扎替尼 Quizartinib急性髓性白血病

奎扎替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Quizartinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

Composition:

LUCiUS

急性髓性白血病

dihydrochloride 2u me equivalent to
Indication:

PHARMACEUTICALS

............... 17.7mg
LuciQuiza is a kinase mnnibnor muicdcu ma
combination with standard cytarabine alld

anthracycline inducfionas
antoracyclibe mnouction and cylaraons
consolidation, and as maintenance monotherapy

LuciQuiza

agposed acutu

sitive as detected bya

' Take LuciOuzat

Quizartinib Tablets

FDA批准

an Lacipuiza tablets orally once datly with or
without food at approximately the same time eac
.See Full Prescribing Information for recommen
LuciQuiza dosage regi

17.7mg

moditications.
en and dosage
Storage: in a dry place and store at 20°C to 25C.
Keep medicine out of reach of Children. Do n

Rx Only

auminister LuciQuiza during Pregnancy and
Lactation.

PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by.

权威认证

LUCIUS
PHOBONACEUTICALS

Thongmang village. Kaythany district,
Vientiane Capital, Laos
Warning: 1o be sold oy retan on nresorint
siereu physicians only, and as directed
Dy the physician.

14 Tablets

口碑质量

适应症:
适用于治疗经FDA批准的测试方法检测为FLT3内串联重复
(ITD)阳性的新诊断急性髓系白血病(AML)成年患者。在诱导
治疗中可与阿糖胞苷和蒽环类联合使用,单药可用于巩固化
疗后的维持治疗。
推荐剂量:
1、奎扎替尼的推荐剂量和剂量调整方案,请阅读说明书。
2、每日口服一次,大约在同一时间服用,随餐或空腹均可。